Patents by Inventor Gavin Thurston

Gavin Thurston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11820815
    Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
  • Publication number: 20230323470
    Abstract: The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient has a tumor with threshold levels of both tumor mutation burden and expression of major histocompatibility complex, and administering to the patient a therapeutically effective amount of programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In some embodiments, the cancer is skin cancer, such as basal cell carcinoma or cutaneous squamous cell carcinoma.
    Type: Application
    Filed: August 25, 2021
    Publication date: October 12, 2023
    Inventors: Matthew G. Fury, Gavin Thurston, Vladimir Jankovic, Nathalie M. Fiaschi, Israel Lowy
  • Publication number: 20230270894
    Abstract: Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
    Type: Application
    Filed: October 25, 2022
    Publication date: August 31, 2023
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston, Richard Tavare
  • Publication number: 20230270837
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Application
    Filed: December 15, 2022
    Publication date: August 31, 2023
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
  • Publication number: 20230220101
    Abstract: The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc? receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc? receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20.
    Type: Application
    Filed: July 27, 2022
    Publication date: July 13, 2023
    Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston
  • Patent number: 11692032
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: July 4, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
  • Publication number: 20230159639
    Abstract: Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.
    Type: Application
    Filed: October 26, 2022
    Publication date: May 25, 2023
    Inventors: Jason T. Giurleo, Dangshe Ma, William Olson, Gavin Thurston, Richard Tavare
  • Publication number: 20230139492
    Abstract: This disclosure relates to novel triple combination therapies of an oncolytic virus, a PD-1 pathway inhibitor, and a CTLA4 inhibitor for treating or inhibiting the growth of a tumor in a patient with cancer.
    Type: Application
    Filed: July 18, 2022
    Publication date: May 4, 2023
    Inventors: Saida Dadi-Mehmetaj, Markus Mohrs, Gavin Thurston
  • Patent number: 11608380
    Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: March 21, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
  • Publication number: 20230037524
    Abstract: The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.
    Type: Application
    Filed: July 5, 2022
    Publication date: February 9, 2023
    Inventors: Xinyuan Zhang, Julie Horowitz, Stefan Semrau, Goncalo Abecasis, Gavin Thurston, Eric Jorgenson, Aris Baras
  • Patent number: 11559576
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: January 24, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
  • Patent number: 11525001
    Abstract: Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: December 13, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jason T. Giurleo, Dangshe Ma, William Olson, Richard Tavare, Gavin Thurston
  • Patent number: 11511001
    Abstract: Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 29, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston, Richard Tavare
  • Patent number: 11434300
    Abstract: The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc? receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc? receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: September 6, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston
  • Publication number: 20220184241
    Abstract: Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 16, 2022
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston
  • Publication number: 20220185900
    Abstract: The present invention provides fully human antibodies that bind to the RET receptor tyrosine kinase, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for treating diseases, disorders, or conditions associated with expression, activation, or signaling of the RET receptor tyrosine kinase gene, or a rearranged form thereof, including cancerous conditions and the pain associated with the cancer, or for alleviating the pain associated with other conditions attributed to, at least in part, by expression, activation or signaling of RET. The antibodies specific for RET may be useful for slowing tumor cell growth or tumor cell proliferation and also for alleviating the pain associated with the cancer and other conditions. The antibodies may also be useful for diagnosis of a disease, disorder or condition associated with RET activation or signaling.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 16, 2022
    Inventors: Christopher Daly, Gavin Thurston, Nicholas Papadopoulos
  • Publication number: 20220112306
    Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.
    Type: Application
    Filed: February 26, 2021
    Publication date: April 14, 2022
    Inventors: Julian Andreev, Andres Perez Bay, Christopher Daly, Frank Delfino, Amy Han, Thomas Nittoli, William Olson, Gavin Thurston
  • Publication number: 20220025030
    Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
    Type: Application
    Filed: June 4, 2020
    Publication date: January 27, 2022
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
  • Publication number: 20220008548
    Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
    Type: Application
    Filed: September 23, 2021
    Publication date: January 13, 2022
    Inventors: Julian Andreev, Nithya Thambi, Frank Delfino, Joel Martin, Gavin Thurston, Katherine Cygnar, Nicholas Papadopoulos
  • Publication number: 20220001000
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Application
    Filed: August 13, 2020
    Publication date: January 6, 2022
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston